New imidazo[1,2-a]pyridine/pyrimidine-1,2,3-triazoles (IPTs) designed by specific structural modifications of zolpidem exhibited superior antitubercular activity than the parent compound.
A new series of quinoline‐1,2,3‐triazole derivatives (6a‐j and 10a‐j) were designed based on the molecular hybridization concept and the molecules were synthesized by employing a click chemistry approach. The pharmacophoric units (quinoline and 1,2,3‐triazole) are linked through either an ether or an amide functionality; such a simple structural modification of the linker group significantly enhanced the anti‐tubercular activity of the molecules and all the amide derivatives showed better inhibition activity as compared to their ether analogs. However, these compounds did not inhibit significantly the growth of tested bacterial strains: the activity profile is similar to that observed for standard anti‐TB drugs indicating the specificity of these compounds towards the M.tuberculosis strain. The molecular docking studies of the active compounds with two target enzymes (Inh A and CYP121) of M.tuberculosis revealed the strong binding interactions, mainly through hydrogen bonding, between the molecules and the target receptors. Furthermore, prediction of in silico‐ADME (A: absorption, D: distribution, M: metabolism and E: excretion) parameters indicated that these compounds have an excellent oral bioavailability. The results suggest that these quinoline‐1,2,3‐triazole hybrids are a promising class of molecular entities for the development of new anti‐tubercular leads.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.